Dated: July 12, 1999.

Margaret M. Dotzel,

Acting Associate Commissioner for Policy Coordination.

[FR Doc. 99–18234 Filed 7–16–99; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 99N–1833]

SoloPak Laboratories, Inc.; Withdrawal of Approval of 1 New Drug Application and 38 Abbreviated New Drug Applications; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

SUMMARY: The Food and Drug Administration (FDA) is correcting a notice that appeared in the **Federal Register** of June 21, 1999 (64 FR 33097). The document announced the withdrawal of approval of 1 new drug application (NDA) and 38 abbreviated new drug applications (ANDA's) held by SoloPak Laboratories, Inc. The document omitted language explaining that the sponsor voluntarily removed the products from the market because of discrepancies concerning the data submitted to support continued approval of the applications. This document corrects that omission.

EFFECTIVE DATE: JULY 19, 1999.

FOR FURTHER INFORMATION CONTACT: Olivia A. Pritzlaff, Center for Drug Evaluation and Research (HFD–7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–594–2041.

In FR Doc. 99–15581, appearing on page 33097 in the **Federal Register** of Monday, June 21, 1999, the following correction is made: Onpage 33098, immediately preceding the table, add the following two paragraphs to read as follows:

Recently, FDA became aware of discrepancies concerning the data submitted to support continued approval of the following ANDA's held by SoloPak:

ANDA 88–457; Heparin Lock Flush Solution USP, 10 units/milliliter (mL); and

ANDA 88–519; Phenytoin Sodium Injection USP, 50 milligrams (mg)/mL.

After careful review of inspectional findings, the agency determined that there was sufficient justification to initiate proceedings to withdraw approval of the two products listed above. SoloPak was notified in writing of the determinations and, in accordance with § 314.150(d) (21 CFR 314.150(d)), was offered an opportunity to permit FDA to withdraw the applications. Subsequently, in letters dated December 15, 1998, and March 31, 1999, SoloPak requested withdrawal under § 314.150(d) of the applications listed in the following table, thereby waiving its opportunity for a hearing.

Dated: July 8, 1999.

Janet Woodcock,

Director, Center for Drug Evaluation and Research.

[FR Doc. 99–18235 Filed 7–16–99; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Statement of Organization, Functions, and Delegations of Authority; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

SUMMARY: The Food and Drug Administration (FDA) is correcting a notice that appeared in the **Federal Register** of July 6, 1999 (64 FR 36361). The document announced that FDA is being restructured to create a more streamlined and efficient Office of the Commissioner that will provide leadership without compromising programmatic effectiveness. The restructuring document, which became effective on June 20, 1999, was published with an inadvertent error. This document corrects that error.

FOR FURTHER INFORMATION CONTACT: LaJuana D. Caldwell, Office of Policy (HF–27), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–7010.

In FR Doc. 99–17019, appearing on page 36361 in the **Federal Register** of Tuesday, July 6, 1999, the following correction is made:

1. On page 36362, in the first column, in the fourth paragraph, beginning in the twelfth line ''Center for Devices and Radiological Health'' is corrected to read ''Center for Drug Evaluation and Research.''

Dated: July 12, 1999.

Margaret M. Dotzel,

Acting Associate Commissioner for Policy Coordination.

[FR Doc. 99–18236 Filed 7–16–99; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Availability of New E-mail Service for Government-Owned Inventions Available for Licensing and Cooperative Research Opportunities

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The Office of Technology Transfer (OTT), National Institutes of Health desires to announce the availability of a new e-mail service concerning government-owned inventions available for licensing and cooperative research opportunities.

OTT has initiated a Techbrief e-mail list service to inform companies, institutions and anyone interested in biomedical technology transfer about NIH and FDA technologies available for licensing, as well as Cooperative Research and Development (CRADA) opportunities with PHS scientists.

ADDRESSES: Persons may subscribe to the list at no charge upon request to: Dr. George Keller, Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852 (telephone: (301) 496–7735, extension 246; fax: (301) 402–0220, e-mail: gk40j@nih.gov). Please include: company affiliation, title, address, phone and fax numbers, and e-mail address. A convenient form is available at the OTT web site: http://www.nih.gov/od/ott/.

Dated: July 12, 1999.

Jack Spiegel, PhD.,

Director, Division of Technology Development & Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 99–18373 Filed 7–16–99; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of